Anaplastic large cell lymphoma epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
===Gender<small><ref Name= Cancer.ca> Anaplastic large cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/anaplastic-large-cell-lymphoma/?region=on Accessed on October 7, 2015</ref></small>=== | ===Gender<small><ref Name= Cancer.ca> Anaplastic large cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/anaplastic-large-cell-lymphoma/?region=on Accessed on October 7, 2015</ref></small>=== | ||
* Males are more commonly affected with anaplastic large cell lymphoma than females | * Males are more commonly affected with anaplastic large cell lymphoma than females | ||
== Epidemiology and Demographics== | |||
ALK negative ALCL represents 2%-3% of all [[non-Hodgkin's lymphomas]] ([[NHL]]) and 12% of all [[T-cell NHL]].<ref name="ALK">{{cite web|url=http://www.sciencedirect.com/science/article/pii/S104084281200131X|title=Anaplastic large cell lymphoma, ALK-negative}}</ref> | |||
===Age=== | |||
ALK negative ALCL affects primarily adults between 40-60 years old. | |||
===Gender=== | |||
There is a modest male predominance in the prevalence of the disease.<ref name=Swerdlow>{{cite book | last = Swerdlow | first = Steven | title = WHO classification of tumours of haematopoietic and lymphoid tissues | publisher = International Agency for Research on Cancer | location = Lyon, France | year = 2008 | isbn = 9789283224310 }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 20:21, 9 October 2015
Anaplastic large cell lymphoma Microchapters |
Differentiating Anaplastic large cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Anaplastic large cell lymphoma epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Anaplastic large cell lymphoma epidemiology and demographics |
FDA on Anaplastic large cell lymphoma epidemiology and demographics |
CDC on Anaplastic large cell lymphoma epidemiology and demographics |
Anaplastic large cell lymphoma epidemiology and demographics in the news |
Blogs on Anaplastic large cell lymphoma epidemiology and demographics |
Directions to Hospitals Treating Anaplastic large cell lymphoma |
Risk calculators and risk factors for Anaplastic large cell lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Anaplastic large cell lymphoma is a common disease that tends to affect children or young adults. Males are more commonly affected with anaplastic large cell lymphoma than females.[1]
Epidemiology and Demographics
Age[1]
- Patients of all age groups may develop anapastic large cell lymphoma
- Anaplastic large cell lymphoma is a common disease that tends to affect children or young adults
- Anaplastic large cell lymphoma, ALK-positive usually affects younger individuals
- Anaplastic large cell lymphoma, ALK-negative usually affects older individuals
Gender[1]
- Males are more commonly affected with anaplastic large cell lymphoma than females
Epidemiology and Demographics
ALK negative ALCL represents 2%-3% of all non-Hodgkin's lymphomas (NHL) and 12% of all T-cell NHL.[2]
Age
ALK negative ALCL affects primarily adults between 40-60 years old.
Gender
There is a modest male predominance in the prevalence of the disease.[3]
References
- ↑ 1.0 1.1 1.2 Anaplastic large cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/anaplastic-large-cell-lymphoma/?region=on Accessed on October 7, 2015
- ↑ "Anaplastic large cell lymphoma, ALK-negative".
- ↑ Swerdlow, Steven (2008). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer. ISBN 9789283224310.